Xilio Therapeutics Inc [XLO] stock prices are up 11.40% to $1.27 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The XLO shares have gain 15.45% over the last week, with a monthly amount glided 36.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xilio Therapeutics Inc [NASDAQ: XLO] stock has seen the most recent analyst activity on December 21, 2022, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $7. Previously, H.C. Wainwright started tracking the stock with Buy rating on January 10, 2022, and set its price target to $36. On November 16, 2021, Raymond James initiated with a Outperform rating and assigned a price target of $31 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $32 on November 16, 2021. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on November 16, 2021.
The stock price of Xilio Therapeutics Inc [XLO] has been fluctuating between $0.50 and $1.93 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Xilio Therapeutics Inc [NASDAQ: XLO] shares were valued at $1.27 at the most recent close of the market. An investor can expect a potential return of 451.18% based on the average XLO price forecast.
Analyzing the XLO fundamentals
Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -8.52%, Pretax Profit Margin comes in at -8.35%, and Net Profit Margin reading is -8.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.84, Equity is -2.15 and Total Capital is -1.75. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1734 points at the first support level, and at 1.0767 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3233, and for the 2nd resistance point, it is at 1.3765.
Ratios To Look Out For
It’s worth pointing out that Xilio Therapeutics Inc [NASDAQ:XLO]’s Current Ratio is 1.67. In addition, the Quick Ratio stands at 1.67 and the Cash Ratio stands at 1.61. Considering the valuation of this stock, the price to sales ratio is 12.58, the price to book ratio is 2.66.
Transactions by insiders
Recent insider trading involved Frankenfield Christopher James, Chief Financial Officer, that happened on Jan 02 ’25 when 6954.0 shares were sold. SVP, FINANCE AND ACCOUNTING, Brennan Kevin M. completed a deal on Jan 02 ’25 to sell 1803.0 shares. Meanwhile, 10% Owner GILEAD SCIENCES, INC. bought 1.76 million shares on Dec 18 ’24.
